Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
Authors
Keywords
AEs, mCRC, Prophylaxis, Regorafenib, Treatment
Journal
Clinical & Translational Oncology
Volume 16, Issue 11, Pages 942-953
Publisher
Springer Nature
Online
2014-09-15
DOI
10.1007/s12094-014-1212-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
- (2014) A. Grothey et al. ONCOLOGIST
- Aflibercept—a Decoy VEGF Receptor
- (2014) Kristen K. Ciombor et al. Current Oncology Reports
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer
- (2013) Sriram Yennurajalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact
- (2013) Rajesh V. Lalla et al. SUPPORTIVE CARE IN CANCER
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
- (2012) D Strumberg et al. BRITISH JOURNAL OF CANCER
- Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
- (2012) Wei-Xiang Qi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines
- (2011) D. E. Peterson et al. ANNALS OF ONCOLOGY
- Cancer-related fatigue: a practical review
- (2011) M. P. O. Campos et al. ANNALS OF ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Pyrazinamide-induced maculopapular rash
- (2011) Faisal Imam et al. INDIAN JOURNAL OF DERMATOLOGY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
- (2008) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
- (2008) M. E. Lacouture et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started